Protection conferred by COVID-19 vaccination, prior SARS-CoV-2 infection, or hybrid immunity against Omicron-associated severe outcomes among community …
Introduction We assessed protection from coronavirus disease 2019 (COVID-19) vaccines
and/or prior severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection …
and/or prior severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection …
Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI …
Background The effectiveness of SARS-CoV-2 vaccines in older adults living in long-term
care facilities is uncertain. We investigated the protective effect of the first dose of the Oxford …
care facilities is uncertain. We investigated the protective effect of the first dose of the Oxford …
Marked increase in avidity of SARS-CoV-2 antibodies 7–8 months after infection is not diminished in old age
D Pichler, M Baumgartner, J Kimpel… - The Journal of …, 2021 - academic.oup.com
The kinetics of immunoglobulin G (IgG) avidity maturation during severe acute respiratory
syndrome coronavirus-2 (SARS-CoV-2) infection obtained from 217 participants of the Ischgl …
syndrome coronavirus-2 (SARS-CoV-2) infection obtained from 217 participants of the Ischgl …
Risk of COVID-19 death in adults who received booster COVID-19 vaccinations in England
IL Ward, C Robertson, U Agrawal, L Patterson… - Nature …, 2024 - nature.com
The emergence of the COVID-19 vaccination has been critical in changing the course of the
COVID-19 pandemic. To ensure protection remains high in vulnerable groups booster …
COVID-19 pandemic. To ensure protection remains high in vulnerable groups booster …
Correlates of protection against SARS-CoV-2 Omicron variant and anti-spike antibody responses after a third/booster vaccination or breakthrough infection in the UK …
Following primary SARS-CoV-2 vaccination, understanding the relative extent of protection
against SARS-CoV-2 infection from boosters or from breakthrough infections (ie infection in …
against SARS-CoV-2 infection from boosters or from breakthrough infections (ie infection in …
Neutralizing antibodies against SARS-CoV-2 variants of concern elicited by the comirnaty COVID-19 vaccine in nursing home residents
B Sánchez-Sendra, E Albert, J Zulaica, I Torres… - Scientific Reports, 2022 - nature.com
Immunosenescence may impact the functionality and breadth of vaccine-elicited humoral
immune responses. The ability of sera to neutralize the SARS-CoV-2 spike protein (S) from …
immune responses. The ability of sera to neutralize the SARS-CoV-2 spike protein (S) from …
[HTML][HTML] Nursing home deaths after COVID-19 vaccination
TB Wyller, BR Kittang, AH Ranhoff, P Harg… - Tidsskrift for Den …, 2021 - tidsskriftet.no
BACKGROUND In the period 27 December 2020 to 15 February 2021, about 29 400 of
Norway's roughly 35 000 nursing home patients were vaccinated with the mRNA vaccine …
Norway's roughly 35 000 nursing home patients were vaccinated with the mRNA vaccine …
Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden
P Nordström, M Ballin, A Nordström - The Lancet Infectious Diseases, 2022 - thelancet.com
Background Real-world evidence supporting vaccination against COVID-19 in individuals
who have recovered from a previous SARS-CoV-2 infection is sparse. We aimed to …
who have recovered from a previous SARS-CoV-2 infection is sparse. We aimed to …
[HTML][HTML] Robust antibody responses in 70–80-year-olds 3 weeks after the first or second doses of Pfizer/BioNTech COVID-19 vaccine, United Kingdom, January to …
S Subbarao, LA Warrener, K Hoschler… - …, 2021 - eurosurveillance.org
Sera were collected from 185 adults aged≥ 70 years in London to evaluate the immune
response to COVID-19 vaccines. A single dose of Pfizer/BioNtech vaccine resulted in> 94 …
response to COVID-19 vaccines. A single dose of Pfizer/BioNtech vaccine resulted in> 94 …
Effectiveness of previous infection-induced and vaccine-induced protection against hospitalisation due to omicron BA subvariants in older adults: a test-negative, case …
Background Older adults (aged≥ 60 years) were prioritised for COVID-19 booster
vaccination due to severe outcome risk, but the risk for this group is also affected by previous …
vaccination due to severe outcome risk, but the risk for this group is also affected by previous …